article thumbnail

Pharmacist Outreach Can Help Reduce Hypoglycemia Risk | ADA 2025

Drug Topics

Data presented at ADA 2025 showed patients who received outreach from a clinical pharmacist were more likely to be prescribed safer diabetes regimens.

442
442
article thumbnail

Gilead Presents Data Demonstrating Established, Investigational HIV Drugs

Drug Topics

Among the drugs presented, Biktarvy and lenacapavir, teropavimab, and zinlirvimab (LTZ) demonstrate rates of suppression of HIV, and vesatolimod is well tolerated.

415
415
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Physicians Looking to Pharmacists for Patient Engagement in Diabetes Management | ADA 2025

Drug Topics

Jon Easter, RPh, discusses pharmacists’ ability to improve patient engagement in diabetes care following his presentation at the American Diabetes Association’s 85th Scientific Sessions.

329
329
article thumbnail

Pharmacist Outreach Reduces Therapeutic Inertia in T2D | ADA 2025

Drug Topics

Data presented at ADA’s 85th Scientific Sessions showed patients who received physician education with clinical pharmacist outreach had significantly better A1c levels at 6 months compared to usual care.

315
315
article thumbnail

AI-Driven CGM Insights Improved Glycemic Control | ADA 2025

Drug Topics

In an abstract presented at the American Diabetes Association 85th Scientific Sessions, researchers tested the effectiveness of an AI-driven program for improving glycemic control.

473
473
article thumbnail

Q&A: The Evolving Role Pharmacists Play in Team-Based Diabetes Care | ADA 2025

Drug Topics

In a recap of his presentation at the American Diabetes Association’s 85th Scientific Sessions, Jon Easter, RPh, discussed the role of pharmacists in team-based diabetes care.

281
281
article thumbnail

Takeda presents positive results from trial of chronic kidney disease treatment

Pharmafile

The data was presented at the European Renal Association Congress on 6 June 2025 […] The post Takeda presents positive results from trial of chronic kidney disease treatment appeared first on Pharmafile. The Japanese biopharma is now looking ahead to a prospective phase 3 trial of mezagitamab.

116
116